Eric Topol

I mean, they're just cumulative.

This one, you know, there was tremendous improvement, but still not enough.

And I guess you're zooming in on the lead lines that'd be the most important thing to work on today.

Another thing that has come up, there's been trials, as you may, I'm sure you know, because you're all over this field, of chelation.

There's a trial that was run by NIH, supported by NIH, that looked at chelation to prevent coronary disease.

Is there any evidence that people who have a problem with lead would benefit from chelation therapy?

Right.

It's a reservoir that's hard to reckon with.

Yeah.

Now, another thing, you have a substack that is called Plagues, Pollution, Poverty.

And you wrote a really provocative piece in that earlier in April called How Estrogen Keeps Lead and Heart Attack in Check.

Basically, you got into the lead estrogen hypothesis.

Right.

Can you enlighten us about that?

Yeah, I know.

It's really interesting.

I mean, quite provocative.

Should be followed up on for sure.

Just getting to you, you're a physician and epidemiologist, you know, MD, MPH, and you have spent your career on this sort of thing, right?

I mean, is your middle name like lead or, you know, what do you work on all the time?